iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Sets New 12-Month High at $71.74

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE)’s share price reached a new 52-week high during trading on Monday . The company traded as high as $71.74 and last traded at $71.74, with a volume of 941 shares trading hands. The stock had previously closed at $71.72.

iShares U.S. Pharmaceuticals ETF Price Performance

The firm has a market cap of $729.02 million, a price-to-earnings ratio of 6.49 and a beta of 0.58. The firm has a fifty day simple moving average of $68.08 and a two-hundred day simple moving average of $66.93.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Cultivar Capital Inc. purchased a new stake in shares of iShares U.S. Pharmaceuticals ETF during the second quarter valued at $25,000. Rothschild Investment LLC purchased a new stake in iShares U.S. Pharmaceuticals ETF during the 2nd quarter valued at about $26,000. Global Retirement Partners LLC increased its holdings in shares of iShares U.S. Pharmaceuticals ETF by 454.1% in the first quarter. Global Retirement Partners LLC now owns 410 shares of the company’s stock valued at $28,000 after purchasing an additional 336 shares during the period. Mather Group LLC. purchased a new position in shares of iShares U.S. Pharmaceuticals ETF in the second quarter worth about $29,000. Finally, National Bank of Canada FI lifted its holdings in shares of iShares U.S. Pharmaceuticals ETF by 274.0% during the fourth quarter. National Bank of Canada FI now owns 187 shares of the company’s stock worth $35,000 after purchasing an additional 137 shares during the period.

About iShares U.S. Pharmaceuticals ETF

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.